SCHEMBL20116338

SCHEMBL20116338

COC(=O)N1CCC(c2nc(-c3ccnc(Cl)c3)no2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
TSHR P16473 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
SMO Q99835 3/20 0.52
TUBB4A P04350 4/20 0.51
TUBB P07437 4/20 0.51
TUBA3C P0DPH7 4/20 0.51
TUBA1B P68363 4/20 0.51
TUBA4A P68366 4/20 0.51
TUBB4B P68371 4/20 0.51
TUBB3 Q13509 4/20 0.51
TUBB2A Q13885 4/20 0.51
TUBB8 Q3ZCM7 4/20 0.51
TUBA3E Q6PEY2 4/20 0.51
TUBA1A Q71U36 4/20 0.51
TUBA1C Q9BQE3 4/20 0.51
TUBB6 Q9BUF5 4/20 0.51
TUBB2B Q9BVA1 4/20 0.51
TUBB1 Q9H4B7 4/20 0.51
HTT P42858 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116945 0.89 GPR119 (0.52) LMNATSHRSMN1; SMN2TUBB4ATUBB
SCHEMBL20116303 0.85 SMN1; SMN2 (0.55) LMNATSHRSMN1; SMN2SMOTUBB4A
SCHEMBL20116150 0.84 SMN1; SMN2 (0.53) LMNATSHRSMN1; SMN2SMOTUBB4A
SCHEMBL22358304 0.83 SMO (0.48) LMNATSHRSMN1; SMN2SMOTUBB4A
SCHEMBL20116815 0.80 CNR2 (0.47) LMNATSHRSMN1; SMN2HTTHCRTR1
SCHEMBL20116971 0.77 SMO (0.54) LMNATSHRSMN1; SMN2SMOTUBB4A
SCHEMBL22358240 0.76 SMO (0.51) LMNATSHRSMN1; SMN2SMOTUBB4A
SCHEMBL20116964 0.76 GRM5 (0.52) SMN1; SMN2SMOTUBB4ATUBBTUBA3C
SCHEMBL20116613 0.76 SMO (0.53) LMNATSHRSMN1; SMN2SMOTUBB4A
SCHEMBL20116039 0.75 SMO (0.52) LMNATSHRSMN1; SMN2SMOTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 LMNA 1966/4885TSHR 4679/4885SMN1; SMN2 13/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 LMNA 1966/4885TSHR 4679/4885SMN1; SMN2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.